Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Delayed Data from NSDQ)

$41.11 USD

41.11
263,601

+0.28 (0.69%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $41.11 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for AMPH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Amphastar Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 259 178 139 110 90
Receivables 115 89 79 66 46
Notes Receivable 0 0 0 0 0
Inventories 106 104 93 97 111
Other Current Assets 9 8 7 7 10
Total Current Assets 490 378 318 280 255
Net Property & Equipment 283 238 244 260 234
Investments & Advances 15 2 4 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 53 39 22 25 26
Intangibles 613 37 39 41 41
Deposits & Other Assets 26 21 17 5 11
Total Assets 1,513 742 672 631 587
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 93 84 90 96 77
Current Portion Long-Term Debt 0 3 2 12 8
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 126 0 0 0 0
Income Taxes Payable 2 5 9 1 2
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 225 95 104 112 90
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 1 1 1
Convertible Debt 0 0 0 0 0
Long-Term Debt 590 73 75 34 39
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 29 22 22 18 13
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 873 213 226 183 159
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 486 455 422 410 367
Retained Earnings 409 272 180 118 116
Other Equity -8 -9 -7 43 41
Treasury Stock 247 190 150 122 98
Total Shareholder's Equity 639 529 446 449 428
Total Liabilities & Shareholder's Equity 1,513 742 672 631 587
Total Common Equity 639 529 446 449 428
Shares Outstanding 47.90 48.30 47.80 47.50 46.90
Book Value Per Share 13.35 10.95 9.32 9.45 9.12

Fiscal Year End for Amphastar Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 259 306 168 195
Receivables NA 115 121 106 101
Notes Receivable NA 0 0 0 0
Inventories NA 106 110 105 104
Other Current Assets NA 9 6 6 7
Total Current Assets NA 490 543 385 408
Net Property & Equipment NA 283 281 279 243
Investments & Advances NA 15 2 1 2
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 53 41 41 39
Intangibles NA 613 619 626 37
Deposits & Other Assets NA 26 25 20 19
Total Assets NA 1,513 1,545 1,378 774
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 93 223 218 89
Current Portion Long-Term Debt NA 0 0 13 2
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 126 0 0 0
Income Taxes Payable NA 2 31 18 12
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 225 258 251 106
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 590 638 488 73
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 23 25 22
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 873 949 789 225
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 486 478 471 457
Retained Earnings NA 409 373 324 298
Other Equity NA -8 -8 -8 -8
Treasury Stock NA 247 247 197 198
Total Shareholder's Equity NA 639 595 589 549
Total Liabilities & Shareholder's Equity NA 1,513 1,545 1,378 774
Total Common Equity 0 639 595 589 549
Shares Outstanding 48.10 47.90 48.20 48.20 48.10
Book Value Per Share 0.00 13.35 12.35 12.22 11.40